Novo Nordisk Reports Semaglutide Sales of $25.4 Billion in First Three Quarters, Raises Metsera Bid to $10 Billion

On November 5 local time, Novo Nordisk released its Q3 financial report for the first three quarters.Net Sales229.92 billion Danish kroner(Approximately 34.534 billion USD, calculated based on the average exchange rate:1 Danish Krone = 0.1502 US Dollar, the same below), an increase of 15% year-on-year(Calculated by CER)。Revenue in China: 14.874 billion Danish kroner($2.234 billion), an increase of 8% year-on-yearR&D investment of 37.391 billion Danish kroner, approximately 5.616 billion US dollars.

Semaglutide's sales in the first half of the year were169.296 billion Danish kroner(Approximately 25.428 billion USD), accounting for 81.44% of Novo Nordisk's total revenue. The sales of this product in the first three quarters have already surpassed those of K drug.(USD 23.3 billion)And Eli Lilly's Tirzepatide($24.8 billion)。

Semaglutide is sold under 3 brand names, specifically:

• Ozempic Injectable Version for Blood Sugar ReductionSales amount to 952.64Million Danish Kroner($14.309 billion）, an increase of 13% year-on-year, with sales in China reaching 4.288 billion Danish kroner($644 million, -7%)。

• Sugar-lowering Oral Version RybelsusSales amount to 1679Million Danish Kroner($2.522 billion)）, an increase of 5% year-on-year, with sales in China reaching DKK 5.51 billion($83 million, +281%)。

• Weight-Loss Version of WegovySales amounted to 572.42Million Danish Kroner($8.598 billion)）, an increase of 54% year-on-year, with sales in China reaching 950 million Danish kroner($143 million, +481%)）。

In order to further drive performance growth, Novo Nordisk has completed 12 BD deals so far this year, mainly focusing on strengthening its advantages in the cardiovascular-metabolic field.

Source: Insight Database

In addition, Novo Nordisk also collaborates withPfizer Strikes BackMetsera Acquisition Battle. In September this year, Pfizer announced a $73 billion acquisitionMetsera, including $4.9 billion in cash and $2.4 billion in milestone payments. On October 30, Novo Nordisk suddenly made a move, attempting to outbid with a $9 billion offer.

In response to Novo Nordisk's aggressive move, Pfizer has made a new offer, increasing the per-share upfront cash consideration from $47.50 to $60, while reducing the milestone payment from $22.50 per share to $10. The adjusted total transaction value is approximately $8.1 billion.

Now, Novo Nordisk has raised the price again to $10 billion.

Cover Source:Corporate logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If needed, please consult and contact正规医疗机构.

Editor: Crescent Moon

PR Article Coordination: WeChat insightxb